Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway
Harvinder S Chahal1, Giampaolo Trivellin, Chrysanthia A Leontiou
1Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, United Kingdom.
Context:
Somatotroph adenomas harboring aryl hydrocarbon receptor interacting protein (AIP) mutations respond less well to somatostatin analogs, suggesting that the effects of somatostatin analogs may be mediated by AIP.
Objective:
The objective of the investigation was to study the involvement of AIP in the mechanism of effect of somatostatin analogs.
Design:
In the human study, a 16-wk somatostatin analog pretreatment compared with no pretreatment. In the in vitro cell line study, the effect of somatostatin analog treatment or small interfering RNA (siRNA)/plasmid transfection were studied.
Setting:
The study was conducted at a university hospital.
Patients:
Thirty-nine sporadic and 10 familial acromegaly patients participated in the study.
Intervention:
Interventions included preoperative lanreotide treatment and pituitary surgery.
Outcome:
For the human study, GH and IGF-I levels, AIP, and somatostatin receptor staining were measured. For the cell line, AIP and ZAC1 (zinc finger regulator of apoptosis and cell cycle arrest) expression, metabolic activity, and clone formation were measured.
Results:
Lanreotide pretreatment reduced GH and IGF-I levels and tumor volume (all P < 0.0001). AIP immunostaining was stronger in the lanreotide-pretreated group vs. the surgery-only group (P < 0.001). After lanreotide pretreatment, the AIP score correlated to IGF-I changes in females (R = 0.68, P < 0.05). Somatostatin receptor staining was not reduced in samples with AIP mutations. In GH3 cells, 1 nm octreotide increased AIP mRNA and protein (both P < 0.01) and ZAC1 mRNA expression (P < 0.05). Overexpression of wild-type (but not mutant) AIP increased ZAC1 mRNA expression, whereas AIP siRNA knockdown reduced ZAC1 mRNA (both P < 0.05). The siRNA-mediated knockdown of AIP led to an increased metabolic activity and clonogenic ability of GH3 cells compared with cells transfected with a nontargeting control (both P < 0.001).
Conclusion:
These results suggest that AIP may play a role in the mechanism of action of somatostatin analogs via ZAC1 in sporadic somatotroph tumors and may explain their lack of effectiveness in patients with AIP mutations.
Insights
Aryl hydrocarbon receptor interacting protein (AIP) may mediate somatostatin analog effectiveness in sporadic somatotroph tumors via ZAC1. This finding could explain treatment resistance in patients with AIP mutations.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Somatotroph adenomas with aryl hydrocarbon receptor interacting protein (AIP) mutations show reduced response to somatostatin analogs.
- This suggests a potential role for AIP in mediating somatostatin analog efficacy.
Purpose of the Study:
- To investigate the involvement of AIP in the mechanism of action of somatostatin analogs.
- To explore the relationship between AIP, ZAC1, and somatostatin analog response in somatotroph tumors.
Main Methods:
- Human study: 16-week lanreotide pretreatment versus no pretreatment in acromegaly patients (n=49).
- In vitro study: GH3 cell line treated with octreotide or transfected with AIP-targeting siRNA/plasmids.
- Measurements included hormone levels, tumor volume, AIP and somatostatin receptor expression, ZAC1 expression, and cell proliferation.
Main Results:
- Lanreotide pretreatment significantly reduced GH, IGF-I, and tumor volume.
- AIP immunostaining was higher in the lanreotide-pretreated group.
- Octreotide increased AIP and ZAC1 expression in GH3 cells; AIP modulation affected ZAC1 levels and cell proliferation.
- AIP mutations did not correlate with reduced somatostatin receptor staining.
Conclusions:
- AIP appears to mediate somatostatin analog action through ZAC1 in sporadic somatotroph tumors.
- This mechanism may underlie the limited efficacy of somatostatin analogs in patients with AIP mutations.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
The JAK-STAT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Regulation of Food Intake

